A non-extraction high performance liquid chromatography assisted method for the measurement of angiotensin-converting enzyme in serum has been developed. Serum containing the enzyme was incubated with the synthetic substrate, furylacryloylphenylalanylglycylglycine at a concentration approaching 10 times the apparent Km, prior to injection onto a shielded hydrophobic reverse phase high performance liquid chromatography column. This allowed the product to be separated and measured directly without the need for a time consuming protein extraction step. The method is enzymatically sound and avoids the methodological problems associated with automated kinetic assays.
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Angiotensin-converting enzyme (ACE, EC 3.4.15.1, dipeptidyl carboxypeptidase) is a membrane-bound glycoprotein located mainly on the capillary endothelium' where it cleaves a dipeptide from the carboxy terminus of angiotensin I and bradykinir2 The main source of the enzyme is vascular rich tissue, of which the lung is thought to be the most important although studies on rat tissue3 show the highest ACE activity to be present in testis and epididymis. The principal use of the assay has been in the diagnosis and management of sarcoid due to the ability of epithelioid cells found in sarcoid granulomas to secrete ACE.
Several different methods for the measurement of ACE in serum (SACE) have previously been developed using n a t~r a l~~~ or artificial substrates6-' and employing radioisotopic,* spectrofluoro-metric9 or UV detection of products to quantify enzyme activity. Some of these methods have been adapted for use on automated routine laboratory analysers.'OJ'
Here we describe a non-extraction high performance liquid chromatography (HPLC) method which overcomes the disadvantages of previous spectrophotometric methods by separating substrate from product which allows us to use a Correspondence: Dr M N Badminton.
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substrate concentration of approximately 10 times the apparent Km.
MATERIALS AND METHODS

Reagents
Furylacryloylphenylalanylglycylglycine (FAPGG) and furylacryloylphenylalanine (FAP) were purchased from Sigma Chemical Co. Ltd (Poole, UK) as were ACE Reagent, ACE Calibrator, ACE Control-N (normal), ACE Control-E (elevated). Carbamazepine was obtained from Geigy Pharmaceuticals (Horsham, UK). All other reagents were AnalaR grade from BDH Chemicals Ltd (Poole, UK).
Serum samples
Blood was sampled by venepuncture and serum separated prior to storage at -20 "C until assayed.
Chromatography assisted assay method
Substrate buffer solution was made by dissolving the FAPGG in Tris buffer prior to adjusting the pH to 8 -2 with phosphoric acid. All assay reagents were preincubated in a water bath at 37 "C before use. The assay was started by adding 4OOpL substrate buffer solution (12-5 mmol/L FAPGG in 0.1 mol/L Tris phosphate buffer pH 8 -2 ) to plastic tubes containing 50 pL serum and 50 pL sodium chloride buffer solution (1 mol/L chloride in 0.1 mol/L Tris phosphate buffer pH 8.2). The final concentrations in the assay were 10 mmol/L FAPGG and 100mmoVL chloride. The tubes were vortexed, incubated for 15 min at 37 "C before the reaction was stopped with 1 mL of internal standard/stop solution (450 pmol/L EDTA to stop the reaction, 170pmol/L carbamazepine as internal standard in 0 -1 mol/L potassium phosphate buffer p H 7.0). The substrate and product of the reaction were then separated by injecting 20 pL onto a 15 cm Supelcosil LC-Hisep HPLC column (Supelchem UK Ltd, Saffron Walden, UK) fitted with a precolumn 0 . 5 prn frit filter, followed by isocratic elution with 0.1 mol/L potassium phosphate buffer p H 7 -0 containing 20% acetonitrile (v/v) at a flow rate of 1 -4 mL/min. The HPLC system consisted of a PU 4015 pump and a LC-UV variable wavelength detector with an 8 pL flow cell volume and a 1 cm light path. Sample injection was with either a manual Rheodyne valve or an autoinjector model SpH125 Fix (Spark Holland, Emmen, Netherlands) and signal output was monitored with a SP 4100 computing integrator (Spectraphysics, Santa Clara, USA). The HPLC system was run at room temperature and the eluate monitored at a wavelength of 304 nm with a full scale deflection of 1.28 absorbance units.
Calculations
ACE activity was calculated using the peak height ratio of hydrolysed FAP to internal standard. This was compared with the peak height ratio obtained from a standard solution containing 100 pnol/L FAP. One unit of ACE activity was that which converted 1 p o l of FAPGG to FAP per minute at 37 "C. Line fitting for the Lineweaver-Burk plot was calculated by non-weighted linear regression analysis using SPSS/PC + software.
Automated kinetic assay
Serum was also assayed for ACE using the commercial method obtained from Sigma Diagnostics which involves monitoring the hydrolysis of FAPGG by the decrease in absorbance at 340nm on a Cobas Mira analyser (Roche Products Ltd, Welwyn Garden City, UK).
RESULTS
Separation and quantification
The substrate (FAPGG) was separated from the product (FAP) so that F A P could be measured s P I 1s directly by monitoring the eluant at 304nm ( Fig. 1 ). Standard solutions of F A P showed linearity between 10 pmol/L and 1 mmol/L. FAP production was linear until at least 30 min ( Fig. 2 ) and 15 min was chosen as a suitable incubation time. As previously reported,6 EDTA at a final concentration of 300 pmol/L was shown to stop the reaction.
Optimization of assay method
All assays to optimize the method were performed in triplicate on a normal serum and results presented as means. Optimum p H was found t o be 8 -2 2 0 . 1 which is consistent with previously reported values.' Two buffer systems were compared, sodium borate at 80 rnmol/L, 120 mmol/L and 160 mmol/L versus 100 mmol/L Tris phosphate all a t p H 8 -2 . The buffer system giving the highest activity for ACE at 5 mmol/L FAPGG was 80mmol/L sodium borate. However, a Lineweaver-Burk plot (Fig. 3) shows a n Using the above assay conditions the optimum chloride concentration was determined as 100 mmol/L added chloride (Fig. 4 ). This differed from the optimum chloride concentration of 300 mmol/L found by other groups7-" so the assay was repeated at a substrate concentration of 1 mmol/L. This showed an overall lower enzyme activity with little variation in enzyme activity at chloride concentrations between 100 and 300mmol/L (Fig. 4 ).
Evaluation of method
Imprecision was determined on commercially available normal control serum (A) and a high patient sample (B) for within-batch and low normal (C) and high normal (D) control sera for between-batch (Table 1) . Samples for determining the reference range (n = 102) were selected from a hospital outpatient population excluding patients with known respiratory or inflammatory disease. The mean ACE activity was 146.4+45-6U/L Between batch (mean? SD). The reference range 74-261 U/L was determined using the 2.5 and 97.5% confidence limits since the distribution showed positive skewing.
The optimized method was used to compare the ACE activity in samples from 29 patients with those obtained using the automated kinetic assay in routine use in our laboratory. The relationship was linear (r = 0-972), with the equation; HPLCassisted SACE = 3-21 x kinetic SACE + 61 -6 (linear regression was performed by the method of DemingI3).
DISCUSSION
The measurement of serum ACE activity has been advocated as a useful test for the diagnosis of sarcoidosis and the monitoring of its treatment with corticosteroids. Investigation of patients with active disease has shown that approximately half have raised SACE activity and of those with elevated SACE activity 90% have sarcoidosis. l4 Our assay is based on the methods described by ChiknasI5 and Holmquist et al. I6 The latter uses the ability of SACE to cleave the dipeptide glycyl-glycine from the N-substituted synthetic tripeptide FAPGG. We have shown that the affinity of the enzyme for FAPGG in the two buffers investigated, Tris and borate, is dependent on chloride concentration. The apparent Km for FAPGG using Tris buffer with 400 mmol/L chloride was 0.56 mmol/L which agrees with previously reported values' and which was similar to the apparent Km measured using borate with 400 mmol/L chloride (0-58 mmol/L). However, using the optimum chloride concentration of 100mmol/L the apparent Kms were 1.33 and 4-03 mmol/L for Tris and borate, respectively. To achieve V , , a concentration of approximately 10 times the apparent Km should be used to avoid the effects of decreasing substrate concentration on the rate of substrate hydrolysis.I2 In previously reported assays that used F A P G G as s~b s t r a t e ,~. " a substrate concentration well below 10 times the apparent Km had to be used as a higher FAPGG concentration would have resulted in an unmeasurably high initial absorbance. We have overcome this problem by injecting an aliquot of the reaction mixture onto a direct injection HPLC column which separates the product of the reaction from the large amount of substrate still present, thereby allowing us to measure FAP production directly. All the values for SACE measured using our method are very much higher than those for any previously reported method (HPLC-assisted SACE = 3 -21 x kinetic SACE + 61.6) due to the high substrate concentration which allows us to measure enzyme activity at approximately 88% of V , , .
Using a substrate concentration of exactly 10 times the apparent Km Hepes and borate) has been reported.'J' We have found the maximal enzyme activity occurs at a chloride concentration of 100 mmol/L which is approximately that found in serum. These results, namely the effect of substrate concentration, choice of buffer, pH and different chloride concentrations may help to explain the large differences in reference ranges reported in the literature and which have been the subject of a recent debate. [17] [18] [19] They also reaffirm the need for agreement on standard conditions for a kinetic assay and for an accurate reference method employing sound enzymatic principles.
The use of HPLC for the assay of ACE levels in serum has been reported previously using a different synthetic substrate, hippuryl-l-histidyl-L-leu~ine,'~ and the naturally occurring substrate Angiotensin I.4 However, the first method requires an additional and time consuming protein extraction step prior to injection onto the HPLC column and the second method requires a precolumn fluorescence derivatization step. The advantage of using a shielded hydrophobic reverse phase column for direct injection of biological material is that it eliminates the time consuming extraction step and the problem of incomplete extraction. Another advantage of this method is lack of interference by sample lipaemia or haemolysis since high molecular weight substances are eluted with the solvent front.
In conclusion, the assay method presented here is enzymatically sound and avoids many of the methodological problems found with automated kinetic assays. It also avoids the time consuming extraction or derivatization steps involved in previously reported HPLC-assisted methods. A recent review article on the value of SACE activities in patients with sarcoidosis20 highlighted their limited usefulness except in monitoring patients on steroid treatment. This has resulted in fewer requests for the measurement of SACE activity and we feel that our method has many advantages if the assay is to become a regional o r supra-regional test as the authors' of the review article recommend.20
